---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-027356"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2026-08-12T20:52:25+00:00"
generated_at: "2026-08-12T20:53:08.873150+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Reviva Q2 net loss narrows to $2.4M; cash $19.9M; brilaroxazine patent extension pursued

## Summary
- Net loss $2.4M ($0.19/share) for Q2 2026 vs $6.1M ($2.40/share) year ago; per-share reflects 1:20 reverse split.
- Cash and equivalents $19.9M at June 30, 2026 vs $14.4M at Dec 31, 2025.
- Filed US composition-of-matter patent for new brilaroxazine form to extend exclusivity through 2046.
- FDA feedback on using new formulation in RECOVER-2 trial and NDA expected Q4 2026; bioequivalence study planned Q4 2026.
- Patient enrollment in RECOVER-2 Phase 3 trial expected 1H 2027, subject to additional financing.

## SEC filing metadata
- accession: 0001437749-26-027356
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2026-08-12T20:52:25+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774926027356/0001437749-26-027356-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774926027356/rvph20260729_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-027356
- JSON: https://secwatch.observer/filing/0001437749-26-027356.json
- Plain text: https://secwatch.observer/filing/0001437749-26-027356.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.